- Medical Director, Heart Valve and Structural Heart Disease
Research and Professional Experience
Dr. Brian Whisenant is an interventional cardiologist with a focus on catheter-based therapies for heart valve and
structural heart disease. He has been the local, primary investigator for numerous trials for the following procedures:
- Transcatheter mitral valve repair
- Transcatheter aortic valve replacement (TAVR)
- Left atrial appendage closure as an alternative to chronic, oral anticoagulation (blood thinners) for the prevention of stroke in atrial fibrillation.
Current Research Projects
- Partner 3 Trial: To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve in patients with severe, symptomatic aortic stenosis who are at low operative risk for standard aortic valve replacement.
- COAPT Clinical Trial: To confirm the safety and effectiveness of the MitraClip System for the treatment of moderate-to-severe or severe functional mitral regurgitation (FMR) in symptomatic heart failure subjects who are treated per standard of care and who have been determined by the site's local heart team as not appropriate for mitral valve surgery.
This randomized controlled trial will provide the opportunity to strengthen or add labeling claims regarding safety and clinical benefits of the MitraClip System for symptomatic heart failure patients with moderate-to-severe or severe functional mitral regurgitation.
As part of the COAPT trial, a subset of patients will be registered in the cardiopulmonary exercise sub-study. The objective of this sub-study is to evaluate the exercise responses in a sub-cohort of COAPT subjects who receive MitraClip device (Device group) compared to the Control group who do not receive MitraClip device.